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Abstract
Candida infections in the elderly are an important and expanding clinical problem, with significantly higher mortality in this 
group than in younger patients. The increasing problem of invasive Candida infections may be related to higher prevalence 
of immunocompromised older people and the emergence of treatment resistance. Older people, especially the frail and criti-
cally ill, are at higher risk of medication-related harmful effects due to changes in pharmacokinetics and pharmacodynamics, 
which may be further complicated by organ dysfunction, diminished homeostatic control, co-morbidities and polypharmacy. 
Here, we review the available options for the treatment of Candida infections and provide insights into the challenges sur-
rounding the optimal use of antifungal drugs in the elderly.
Key Points 
Candida infections are a growing problem in elderly 
patients, with significant mortality in this group.
Treatment in the elderly requires careful consideration 
of benefit and harm in the selection of both the drug and 
dose regimen.
Therapeutic drug monitoring can be recommended for 
selected antifungal agents.
1 Introduction
Candida species are part of the normal human microbiota 
and can be found in the oropharynx, oesophagus, gastro-
intestinal tract and vagina. Local or invasive infection can 
occur as a result of a compromised immune system. Pre-
disposing factors such as cancer, the use of immunosup-
pressants and broad-spectrum antimicrobial agents, and 
co-morbidities such as diabetes mellitus are all risk factors 
for an invasive candida infection and are common in older 
patients [1]. Although systemic therapy is often indicated, 
mucosal infections and Candida in urine are not consid-
ered to be invasive disease. Invasive Candida infections 
are associated with high morbidity and mortality [2]. The 
most important Candida species causing invasive disease 
are C. albicans, C. glabrata, C. krusei, C. parapsilosis and 
C. tropicalis [1]. Rapid initiation of appropriate antifungal 
therapy with adequate exposure is needed to achieve optimal 
treatment outcomes [2, 3]. The aim of this review is to dis-
cuss the epidemiology of Candida infections in the elderly 
(patients over the age of 65 years) and provide an overview 
of diagnostics tests to enable rapid diagnosis. The specific 
drug classes and their pharmacodynamic and pharmacoki-
netic properties are discussed and considerations in relation 
to their use in elderly are highlighted. Finally, this review 
discusses the importance of an antifungal stewardship (AFS) 
programme to provide optimal patient care in older people 
with invasive Candida infections.
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2  Epidemiology of Invasive Candida 
Infection
The incidence of candidaemia and invasive Candida infec-
tions in the elderly is increasing. In many studies, over half 
the cases of candidaemia occur in patients over the age of 
65 years, and the mortality is significantly higher in the 
elderly. A recent large prospective multicentre study of 
29 Spanish hospitals showed that the infecting Candida 
species did not differ between younger and older patients, 
although patients over 75 years of age received inadequate 
antifungal treatment more often than younger patients [4]. 
The overall mortality was significantly higher in older 
patients. A single-centre study of 140 cases of candidae-
mia produced similar findings [5]. The 30-day mortal-
ity in a 5-year retrospective Italian study of 302 patients 
with candidaemia was significantly higher in older than in 
younger patients, with a trend towards a greater antifun-
gal resistance in the older group [1]. Comparable findings 
have been reported in geographically diverse locations, 
such as China and Brazil [6, 7]. The risk factors described 
for candidaemia in the elderly include chronic pulmonary 
and cardiovascular disease, chronic renal failure, diabetes 
mellitus and a higher Charlson Comorbidity Index, whilst 
the ‘classic’ risk factors, such as haematological malig-
nancies, neutropenia, transplantation and solid tumours 
are less common in elderly patients [1, 7]. Candidaemia 
in the elderly is an expanding clinical problem with higher 
mortality in this group, indicating that more timely diag-
nosis and rapid initiation of appropriate antifungal therapy 
is urgently required.
3  Diagnosis of Invasive Candidiasis
The diagnosis of candidaemia and invasive Candida infec-
tion is currently suboptimal and is a contributing factor to 
the high mortality rate. Although it remains the diagnostic 
gold standard, only 50–60% of blood cultures test posi-
tive in patients with invasive Candida infections. Conven-
tional identification methods based on blood and agar plate 
culture typically require 2–4 days to discriminate among 
Candida species. Accurate differentiation between species 
is critical as it guides antifungal therapy. The increasingly 
widespread use of MALDI-TOF (Matrix Assisted Laser 
Desorption Ionization–Time of Flight) technology in 
microbiology laboratories reduces the time to identifica-
tion of the organism isolated from 24–48 h to a time of 3 h 
or less and there are now protocols for the identification of 
Candida directly from positive blood culture bottles, with-
out the need to subculture to agar plates [8]. However, this 
still relies on a positive blood culture as do other new tech-
nologies, for example multiplex polymerase chain reaction 
(PCR) platforms, which can provide results within 1 h of 
culture positivity [8].
The limitations of blood cultures in this setting highlight 
the need for innovative non-culture diagnostic techniques. 
The 1,3-β-d-glucan test measures a cell wall constituent of 
many fungal species and as such is not specific for invasive 
Candida infection [9]. The pooled sensitivity and specificity 
in recent meta-analyses was 75–80 and 80%, respectively, in 
patients with proven or probable invasive fungal infections, 
with even lower sensitivity and specificity for patients with 
intra-abdominal infections without fungi or yeast [9, 10]. It 
is also an expensive test, especially if assays are performed 
in real-time rather than batched. Other non-culture tests, 
such as multiplex PCR or the T2 Candida panel [8], target 
the five to six most common Candida species and therefore 
have an advantage over 1,3-β-d-glucan by providing species 
identification. Non-culture diagnostic tests are not definitive, 
but may identify patients with invasive candidiasis prior to 
confirmatory cultures and can detect some infections that 
would be missed by culture. However, they may also provide 
false-positive results and identify a significant number of 
patients at a very low risk of invasive candidiasis without 
disease and thus must be targeted to the patient population 
at risk for invasive candidiasis and interpreted in the clini-
cal setting.
4  Antifungal Treatment in the Elderly
4.1  Pharmacodynamic and Pharmacokinetic 
Considerations in the Elderly
Optimal management of invasive infectious disease requires 
careful consideration of the impact of aging on pharmacoki-
netics and pharmacodynamics. Figure 1 provides a summary 
of the major factors influencing individualised dose selection 
in older people to achieve optimal health outcomes from 
antifungal treatment [11–14]. While a person’s numerical 
age is a poor guide to dosing, most patients are considered in 
the ‘elderly’ cohort at the age of 65 years and above. Consid-
eration is needed of both intrinsic and extrinsic factors that 
influence pharmacological response and health outcomes.
4.1.1  Variability in Pharmacokinetics 
and Pharmacodynamics in Older People
Variability in pharmacokinetics in older people is a major 
contributor in the variable response to antifungal treatment 
[11]. While pharmacogenetic variation (as observed for 
some antifungal agents, for example) has been identified as 
important, it is less clinically significant in older people. 
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Here, extrinsic factors, such as changes in clearance due 
to the impact of the ageing liver and kidney and drug–drug 
interactions due to polypharmacy, have a greater impact 
on the pharmacokinetics of antifungal drugs [11–16]. 
Frailty has been identified as a major factor contributing 
to pharmacokinetic variability [13, 17], including for some 
antimicrobial agents [18]. Age-associated changes in body 
composition can influence pharmacokinetics and a reduc-
tion in serum albumin concentration can have an impact 
on drug protein binding and therefore on the unbound 
drug concentration [14]. Hepatic clearance by cytochrome 
P450 (CYP) is more likely to be impaired in the elderly, 
although this may be secondary to reduced hepatic blood 
flow and liver size which occur with advancing age [43]. 
Measuring unbound drug concentrations is strongly advo-
cated when monitoring antimicrobial drug therapy in older 
or critically ill patients and for interpreting clearance in 
older people [19, 20].
Pharmacodynamic variability is common in older 
people as well [13, 14]. Older people are generally con-
sidered more sensitive to the effects of medicines, espe-
cially sedatives [11, 14]. Age-related changes in immune 
function (so-called immunosenescence) have the poten-
tial to impact on response to antimicrobial treatment [14, 
21]. The impact on antifungal pharmacodynamics is not 
well-understood but can contribute to the variability in 
response.
Older people, especially the frail and critically ill, are 
at substantially higher risk of medication-related harmful 
effects from treatment [19, 21]. Age-related changes in phar-
macokinetics and pharmacodynamics are a major contribu-
tor, further complicated by organ dysfunction, diminished 
homeostatic control as well as co-morbidities and polyphar-
macy [11, 13, 14].
4.1.2  Evidence to Guide Dose Individualisation in Older 
People
There is limited pharmacokinetic information that is directly 
relevant to frail older people, with multiple health problems, 
organ dysfunction and polypharmacy. High-quality trial 
evidence is lacking, so clinicians have to rely on clinical 
pharmacological principles to guide drug and dose selec-
tion [13]. Stott and Hope [22] highlight the challenge of 
limited real-word data to guide therapeutic drug monitoring 
(TDM) and the lack of information linking target antifun-
gal concentrations and clinical outcomes, such as the fungal 
prophylaxis or treatment of invasive fungal disease. Aging 
is an important consideration in both drug and dose regimen 
selection, together with careful monitoring of benefit and 
harm, especially in frail critically ill older patients (Fig. 1).
4.2  Drugs
4.2.1  Echinocandins
The echinocandins inhibit the synthesis of 1,3-β-d-glucan. 
The currently available drugs of this class include caspo-
fungin, anidulafungin and micafungin. These agents tar-
get the fungal cell wall, instead of cell components which 
are also present in mammalian cells, resulting in reduced 
toxicity [23]. The echinocandins are recommended by the 
Infectious Diseases Society of America (IDSA) and the 
European Society for Clinical Microbiology and Infectious 
Diseases (ESCMID) guidelines as the first-line treatment 
of invasive candidiasis [2, 3]. As a class, these agents are 
generally well-tolerated. Adverse events most frequently 
observed in patients are nausea, elevated hepatic enzymes, 
rash and phlebitis [24]. The favourable characteristics of 
Fig. 1  Pharmacodynamic and pharmacokinetic considerations in older people. RCT randomised controlled trial
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the echinocandins when compared with other antifungal 
agents include fungicidal activity, limited resistance, excel-
lent safety profile and few drug–drug interactions [25–27]. 
The echinocandins are administered once daily at fixed 
doses and are only available for parenteral use [28]. Dose 
adjustments for the echinocandins are not required for older 
patients. Studies in healthy elderly demonstrated no signifi-
cant change in pharmacokinetics compared with healthy 
non-elderly for all three echinocandins. Caspofungin and 
anidulafungin are effective and safe for the treatment of inva-
sive candidiasis in elderly patients, despite higher disease 
severity scores, greater likelihood of decreased organ func-
tion and greater likelihood of concomitant drug use [29, 30].
The echinocandins are not cleared renally, and therefore 
dose adjustment in older patients with renal impairment is 
not required. Drug–drug interactions are uncommon since 
all three agents are not transported by P-glycoproteins [28]. 
Anidulafungin is not hepatically metabolised and caspo-
fungin and micafungin undergo minimal degradation by 
CYP isoenzymes. Nonetheless, caspofungin degradation 
has been shown to be enhanced by strong CYP3A4 induc-
ers and both agents may inhibit CYP3A4 to some extent. 
The limited drug–drug interactions in geriatric patients are 
desirable considering the frequent use of concomitant drugs. 
Although the metabolism of caspofungin via CYP is a minor 
pathway, dose adjustment for caspofungin is recommended 
in patients with mild or severe liver impairment. The lack 
of an oral formulation and daily administration makes the 
echinocandins less suitable for ambulatory use. Comparative 
trials between the echinocandins, primarily micafungin and 
fluconazole demonstrated potential superiority of echino-
candins over fluconazole in prevention of fungal infections 
[31]. The use of echinocandins in the ambulatory setting is 
currently being investigated for a new ‘long-acting’ echi-
nocandin, rezafungin. Rezafungin has the same favourable 
characteristics as the other echinocandins but has been 
developed for once-weekly intravenous or subcutaneous 
administration [32].
4.2.2  Azoles
The azole antifungal agents include fluconazole, itra-
conazole, voriconazole, posaconazole and isavuconazole. 
The mechanism of action is the inhibition of lanosterol 
14α-demethylase, blocking the synthesis of ergosterol and 
resulting in impaired membrane stability and the accumula-
tion of precursors leading to fungistatic or fungicidal effects 
[23]. The azole agents demonstrate activity against most 
Candida species. The IDSA and ESCMID guidelines rec-
ommend fluconazole in patients who are not critically ill and 
are considered unlikely to be infected with an azole-resistant 
species. Fluconazole can also be used for step-down therapy 
in clinically stable patients. Voriconazole can be used as 
step-down treatment of C. glabrata or C. krusei infections 
(if susceptibility results suggest that they are active) or if 
additional mould coverage is required [2, 3]. In the elderly, 
colonisation and infections with non-albicans species, 
including C. glabrata, has been shown to be increased [6, 
33, 34]. In recent studies, the susceptibility to fluconazole 
and voriconazole of non-albicans species isolated from the 
elderly was approximately doubled when compared with the 
susceptibility of isolates obtained from younger patients [6, 
7, 35].
Both voriconazole and fluconazole inhibit CYP3A4 and 
display many drug–drug interactions, resulting in a potential 
increase of adverse events when compared with the echi-
nocandins [36]. Taking this into account, together with the 
increase in non-albicans species with reduced susceptibility 
in elderly patients, fluconazole and voriconazole are not rec-
ommended for the first-line treatment of invasive candidiasis 
in the elderly, but may be relevant for infections with specific 
isolates or as step-down therapy [2, 3].
4.2.2.1 Voriconazole In clinical trials, voriconazole plasma 
concentrations were 80–90% higher in elderly patients (over 
65 years) than in younger patients. However, the prescribing 
information of voriconazole states that, although a relation-
ship between plasma concentrations and age was observed, 
the safety profile of voriconazole in young and elderly 
patients is similar and, therefore, no dose adjustment is 
necessary [37]. Several studies demonstrated a relationship 
between the voriconazole plasma concentration and adverse 
effects, such as elevated liver enzymes and neurotoxicity 
including visual disturbances [38–40].
Voriconazole is metabolised by CYP (predominantly 
CYP2C19), which can be inhibited in patients with severe 
inflammation resulting in higher voriconazole concentra-
tions [41]. Administration of voriconazole to patients with 
mild or moderate hepatic dysfunction resulted in a 223% 
increased exposure when compared with patients with 
normal liver function [37, 42, 43]. Co-morbidities and co-
medication in elderly may result in altered voriconazole 
concentrations [36]. TDM of voriconazole is recommended 
in elderly patients to ensure adequate exposure and avoid 
adverse events [2].
4.2.2.2 Fluconazole In a study in elderly patients (over 
65  years), a higher exposure and longer terminal half-life 
of fluconazole was found than in young volunteers and the 
percentage of fluconazole recovered in urine and the renal 
clearance were generally lower in older patients [44]. Flu-
conazole is primarily eliminated by renal clearance, with 
80% of the drug being excreted unchanged, with flucona-
zole clearance proportional to creatinine clearance. In adult 
patients, the plasma elimination half-life for fluconazole is 
approximately 30  h. In patients with severe renal insuffi-
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ciency (glomerular filtration rate < 20 mL/min) the half-life 
increased to 98 h [44]. Consequently, a dose reduction of 
50% is needed in patients with impaired renal function and 
patients on some renal replacement therapies [36, 44, 45]. 
TDM of fluconazole is currently not recommended in the 
guidelines; however, monitoring of fluconazole concentra-
tions may be appropriate in select patients, such as the criti-
cally ill elderly and patients with renal insufficiency or on 
dialysis [46].
4.2.3  Amphotericin B
Amphotericin B is a polyene isolated from Streptomyces 
nodosus. Amphotericin B has a high affinity for ergosterol 
in the fungal membranes, leading to the formation of trans-
membrane pores, ion leakage and ultimately cell death [47]. 
Amphotericin B is recommended by the IDSA guideline in 
case of intolerance, limited availability or resistance to the 
antifungal agents [2].
Although not investigated thoroughly, the pharmacoki-
netic parameters for amphotericin B do not appear to change 
in elderly and age does not appear to be a relevant covariate 
in pharmacokinetic models for amphotericin B [48]. No dose 
adjustment is recommended with increasing age. Ampho-
tericin B is not metabolised, and thus changes in drug metab-
olism or pharmacokinetic drug–drug interactions do not play 
a significant role [49]. The effectiveness of amphotericin B 
could be reduced in elderly as a recent study found a trend 
towards higher minimum inhibitory concentration (MIC) 
values for C. albicans in elderly than in younger patients 
treated for Candida infections, potentially due to the fact that 
older patients have been exposed more often to antibiotic 
and antifungal treatments, resulting in the selection of less 
susceptible strains [1]. Isolates were, however, still suscep-
tible according to the EUCAST (European Committee on 
Antimicrobial Susceptibility Testing) clinical breakpoints 
(http://www.eucas t.org/clini cal_break point s/).
The use of amphotericin B deoxycholate is limited by its 
toxicity, including infusion-related reactions, hepatotoxicity, 
haematological effects and nephrotoxicity [47]. Nephrotox-
icity during treatment with amphotericin B deoxycholate is 
observed especially in older adults, resulting in increased 
creatinine levels, hypokalaemia and/or hypomagnesaemia 
from the second week of therapy [50]. Electrolyte distur-
bances may be exacerbated by co-administration of thi-
azides and loop diuretics. Toxicity appears to be reduced 
for the lipid formulations (liposomal amphotericin B and 
amphotericin B lipid complex) [51–53]. These formulations 
do not appear to be more toxic in elderly patients than in 
younger patients and efficacy appears to be similar [54, 55]. 
As observed for younger patients, concurrent use of nephro-
toxic treatments should be avoided when possible, which is 
considered more relevant to elderly as these patients more 
often receive nephrotoxic treatments [54, 55].
4.2.4  Flucytosine
Flucytosine is a pyrimidine analogue that is taken up by 
cytosine permease and converted inside the fungal cell to 
its active moiety 5-fluoruracil, leading to inhibition of both 
DNA and RNA synthesis. Flucytosine may be added to the 
treatment for specific patient groups, including those with 
central nervous system (CNS) candidiasis and urinary tract 
infections [2]. Flucytosine is eliminated unchanged via glo-
merular filtration and therefore dosing should be adjusted 
accordingly in renal impairment. In patients with renal fail-
ure, the half-life may be increased up to 20-fold. Since no 
metabolism occurs, pharmacokinetic drug–drug interactions 
are not expected. TDM is recommended for flucytosine as 
the pharmacokinetics are non-linear and the therapeutic win-
dow is narrow [56].
Candida species rapidly develop drug resistance to flucy-
tosine administrated as monotherapy. Therefore, treatment 
with flucytosine should always be combined with another 
antifungal agent such as amphotericin B. Although concur-
rent use may lead to additive or synergistic effects on inva-
sive mycoses, amphotericin B-induced nephrotoxicity may 
lead to the accumulation of flucytosine and increased tox-
icity, including myelosuppression and liver toxicity. Com-
bined treatment with both drugs should therefore be limited 
to specific cases, such as cryptococcosis. When treatment 
with both drugs is necessary, TDM for flucytosine should 
be performed within 72 h after initiation and regularly there-
after [56].
4.3  Therapeutic Drug Monitoring
For anti-infective drugs, including antifungal agents, it is 
both difficult and time-consuming to assess directly whether 
the infection is adequately treated [57]. TDM can be per-
formed to guide dosing of antifungal drugs [58, 59]. For 
TDM to be of benefit, several criteria should be fulfilled 
(Fig. 2) [57–59]. Of the agents used to treat invasive candidi-
asis, voriconazole, posaconazole and flucytosine meet these 
criteria [60]. During treatment, it is recommended to repeat 
measurements of blood concentrations regularly, including 
after the start of treatment, dose adjustments, changed gas-
trointestinal absorption, changed interacting co-medication 
and changed clinical condition of the patient [56, 59]. For 
drugs with a wide therapeutic range, such as fluconazole, 
it seems more practical to empirically administer higher 
doses than performing TDM [59]. A therapeutic range, 
however, is described for this drug (area under the concen-
tration–time curve [AUC]/MIC > 100; 400 AUC mg·h/L; 
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trough > 10–15 mg/L) [59]. A therapeutic range for vori-
conazole (trough 1–5 mg/L, both prophylaxis and treatment) 
and posaconazole is defined for prophylaxis and treatment 
(trough concentration > 0.7 and > 1.25 mg/L, respectively) 
[56, 59, 61, 62]. Figure 2 illustrates when TDM should be 
considered.
TDM is not recommended for the echinocandins or 
amphotericin B by the current guidelines, although stud-
ies report significant variability in echinocandin exposure 
in specific patient populations [56, 63–65]. Decreased and 
potentially inadequate echinocandin exposure induced by 
physiological changes in critically ill patients may result in 
ineffective treatment and drug resistance [63–65]. Although 
in vitro studies have shown a concentration–effect relation-
ship, a clear relationship between exposure and therapeutic 
response is currently lacking [60]. However, sensitivity of 
Candida isolates to echinocandins is decreasing, requiring 
higher doses and indicating that defined therapeutic ranges 
are required to perform TDM [66]. Analytical methods for 
the determination of plasma concentrations of echinocan-
dins are available and can be implemented directly if TDM 
appears to be advantageous [67, 68]. For now, TDM could 
be considered for the echinocandins or amphotericin B if 
patients do not respond to treatment, based on the effective 
pharmacokinetic/pharmacodynamic (PK/PD) parameters 
from in vivo studies [69]. Importantly, to appropriately inter-
pret TDM, the susceptibility of the pathogen to the antifun-
gal drug should be known as well.
In general, TDM is performed by using venous blood 
samples. In addition, dried blood spot sampling can be 
performed for voriconazole and posaconazole TDM. Vori-
conazole saliva concentrations have also been examined as 
an alternative, easily collected specimen [70, 71]. When 
implemented in clinical practice, these alternative sampling 
methods may be a more acceptable and less invasive sam-
pling method for outpatient monitoring of older patients 
[57].
5  Antimicrobial Stewardship
Antimicrobial stewardship (AMS) is an effective and sys-
temic approach to optimise the use of antimicrobial agents 
[72]. AMS programmes have been demonstrated to improve 
patient outcomes, reduce inappropriate antimicrobial use 
and minimise the adverse consequences, such as antimicro-
bial resistance, adverse drug effects and unnecessary costs.
5.1  Antifungal Stewardship in Older People
The aims of AFS overlap with those of AMS; however, 
there are nuanced differences, including that AFS generally 
involves fewer specialties, involves antifungal agents that are 
generally of high cost, and the antifungal pharmacokinet-
ics are complex. Generally, there is a paucity of literature 
evaluating effective AFS recommendations in the elderly; 
however, the same general principles are expected to apply. 
The lack of new agents and growing resistance highlights the 
need to use current antifungal agents judiciously. The goal 
of all AFS programmes should be coordinated quality care 
and better outcomes for patients. Key target areas for AFS 
programs in the elderly include adjusting therapy based on 
diagnostic results, selecting an appropriate agent and dose 
for an appropriate duration, switching from intravenous to 
oral administration when indicated, initiation of TDM and 
guideline concordance. A secondary goal may be reduced 
Fig. 2  Criteria a drug should 
fulfil to perform therapeutic 
drug monitoring (TDM). TDM 
can be performed during the 
treatment of an invasive fungal 
infection or in the prophylaxis 
setting. For several antifungal 
agents TDM is recommended 
during treatment (see text). 
TDM should be repeated 
regularly during treatment. 
TDM can be considered in a 
prophylaxis setting
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antifungal resistance and cost containment. These goals are 
usually achieved by a multidisciplinary team, which should 
include a clinical pharmacist, with knowledge of antifungal 
PK/PD and potential drug–drug interactions, and a medical 
specialist with expertise in interpreting antifungal diagnostic 
testing and clinical mycology. This AFS team should moni-
tor and evaluate antifungal prescribing in relation to local 
resistance patterns, providing regular feedback to prescribers 
and monitor patient safety incidents. This should at least be 
done with key stakeholders, such as haematologists, inten-
sivists, gastrointestinal tract surgeons and respiratory physi-
cians, as appropriate.
5.2  Considerations
Empiric antifungal therapy should be driven by guidelines 
and incidence of antifungal treatment resistance. One study 
reported that patients who receive appropriate therapy have a 
significantly higher overall survival at 12 weeks [73]. Espe-
cially with the use of azoles, drug–drug interactions are a 
significant consideration, which should be reviewed and 
managed. An example of a recommendation could include 
withholding a statin (HMG-CoA reductase inhibitors) while 
the patient completes azole therapy. Key considerations for 
PK/PD include monitoring of liver function when using 
caspofungin. In this case, anidulafungin could be substi-
tuted. Renal function needs to be considered for intravenous 
voriconazole and conventional amphotericin; however, these 
can be overcome by switching patients to oral voriconazole 
or using an alternative formulation of amphotericin (such 
as liposomal), respectively. TDM also plays an important 
role in optimising antifungal use. Finally, antifungal agents 
used in invasive candidiasis are generally of high cost and, 
despite being used less frequently than antibacterial agents, 
they tend to form a significant proportion of the pharmacy 
budgets. A number of published studies show that AFS 
programmes reduce annual hospital expenditure [74, 75]; 
however, this should not be the sole outcome measure of 
AFS success.
5.3  Recommendations
The aims of AFS programmes should be to optimise anti-
fungal use, improve patient care, de-escalate and stop 
antifungal therapy when appropriate, and ensure TDM is 
performed when indicated. This can be achieved by mul-
tidisciplinary AFS teams, who conduct prospective audits 
and give feedback to prescribers within hospitals. The AFS 
team undertakes post-prescription review of patients receiv-
ing antifungal agents and should assess for appropriateness 
of the drug, dose and planned duration. Recommendations 
include stopping unnecessary empiric therapy, de-escala-
tion based on guidelines or diagnostic tests, switching from 
intravenous to oral agents and optimising drug use. Other 
strategic, longer-term goals could include education of pre-
scribers in the facility, regular feedback on antifungal use 
benchmarked to other peer groups or national data, imple-
mentation of evidence-based guidelines and review of local 
fungal resistance rates.
6  Summary and Conclusion
Candida infections are a growing problem in elderly 
patients, with significantly higher mortality in this group. 
Improved diagnostic tests are required to rapidly identify the 
Candida species. When treatment is initiated in the elderly, 
careful monitoring of benefit and harm should be an impor-
tant consideration in the selection of both the drug and dose 
regimen. For selected antifungal agents, TDM is required 
to optimise treatment and prevent adverse effects. An AFS 
should be installed to optimise antifungal treatment.
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